Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ensysce Biosciences Inc
(NQ:
ENSC
)
0.4409
+0.0309 (+7.54%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
145,366
Open
0.3900
Bid (Size)
0.4362 (1)
Ask (Size)
0.4419 (1)
Prev. Close
0.4100
Today's Range
0.3900 - 0.4492
52wk Range
0.3610 - 2.060
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
ENSC Stock Earnings: Ensysce Biosciences Beats EPS, Misses Revenue for Q2 2024
August 14, 2024
ENSC stock results show that Ensysce Biosciences beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
Via
InvestorPlace
Ensysce Biosciences Reports Second Quarter 2024 Financial Results
August 14, 2024
Via
ACCESSWIRE
Performance
YTD
-60.28%
-60.28%
1 Month
+10.50%
+10.50%
3 Month
-25.12%
-25.12%
6 Month
-50.74%
-50.74%
1 Year
-76.92%
-76.92%
More News
Read More
Ensysce Biosciences Provides Key Themes Following IASP 2024 Symposium
August 06, 2024
Via
ACCESSWIRE
Ensysce Biosciences Provides Mid-Year 2024 Update
July 23, 2024
Via
ACCESSWIRE
Ensysce Biosciences Hosts IASP 2024 Symposium and Presents Clinical Dataset
July 09, 2024
Via
ACCESSWIRE
Ensysce Biosciences Discusses Key Themes from the EPHMRA 2024 Annual Meeting
June 27, 2024
Via
ACCESSWIRE
Ensysce Biosciences Announces Partnership to Scale and Manufacture New Drug Candidate
June 25, 2024
Via
ACCESSWIRE
Ensysce Biosciences Announces Major Milestone for Opioid Use Disorder Program
June 06, 2024
Via
ACCESSWIRE
Ensysce Biosciences to Participate in the EPHMRA 2024 Annual Meeting
June 03, 2024
Via
ACCESSWIRE
Ensysce Biosciences Reports First Quarter 2024 Financial Results
May 13, 2024
Via
ACCESSWIRE
ENSC Stock Earnings: Ensysce Biosciences Beats EPS, Misses Revenue for Q1 2024
June 24, 2024
Via
InvestorPlace
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket
June 21, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
June 20, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
June 18, 2024
Via
Benzinga
Ensysce Biosciences’ CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical Edge Magazine
April 25, 2024
Via
ACCESSWIRE
Ensysce Biosciences' Presentation from the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published
April 19, 2024
Via
ACCESSWIRE
Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results
March 15, 2024
Via
ACCESSWIRE
Ensysce Biosciences Regains Compliance with Nasdaq
May 28, 2024
Via
ACCESSWIRE
12 Health Care Stocks Moving In Thursday's Pre-Market Session
May 23, 2024
Via
Benzinga
Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Innovative Overdose Protection Platform
May 20, 2024
Via
ACCESSWIRE
Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
April 09, 2024
Via
ACCESSWIRE
FSR Stock: The $150 Million Reason Fisker Shares Are Moving Today
March 18, 2024
Via
InvestorPlace
Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection
February 21, 2024
Via
ACCESSWIRE
ENSC Stock Earnings: Ensysce Biosciences Misses EPS, Beats Revenue for Q4 2023
March 18, 2024
Via
InvestorPlace
Ensysce Biosciences Receives Positive Nasdaq Listing Determination
February 27, 2024
Via
ACCESSWIRE
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.